Insulin-like growth factor-1 increases intracellular calcium concentration in human primary neuroendocrine pancreatic tumor cells and a pancreatic neuroendocrine tumor cell line (BON-1) via R-type Ca 2+ channels and regulates chromogranin A secretion in BON-1 cells

Neuroendocrinology

Volumn 82, Issue 2, 2005, Pages 87-102

  Mergler, Stefan ^a   Strauss, Olaf ^b   Strowski, Mathias ^a   Prada, Javier ^a   Drost, Adriana ^a   Langrehr, Jan ^a   Neuhaus, Peter ^a   Wiedenmann, Bertram ^a   Ploeckinger, Ursula ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Ca 2+ channels; Chromogranin A; Insulin like growth factors; Neuroendocrine tumors; Pancreas; Patch clamp

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CALCIUM; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL N TYPE; CALCIUM CHANNEL P TYPE; CALCIUM CHANNEL Q TYPE; CALCIUM CHANNEL R TYPE; CHROMOGRANIN A; SNX 482; SOMATOMEDIN C;

ARTICLE; CALCIUM CELL LEVEL; CHANNEL GATING; CONTROLLED STUDY; FLUORESCENCE; HUMAN; HUMAN CELL; IMAGING SYSTEM; MOLECULAR MODEL; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PATCH CLAMP; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; TUMOR CELL; WHOLE CELL;

CALCIUM; CALCIUM CHANNELS, R-TYPE; CELL LINE, TUMOR; CHROMOGRANIN A; CHROMOGRANINS; CULTURE MEDIA; ELECTROPHYSIOLOGY; FLUORESCENT ANTIBODY TECHNIQUE; FLUORESCENT DYES; FURA-2; HUMANS; INSULIN-LIKE GROWTH FACTOR I; NEUROENDOCRINE TUMORS; OLIGONUCLEOTIDES, ANTISENSE; PANCREATIC NEOPLASMS; PATCH-CLAMP TECHNIQUES; PHENOTYPE; TUMOR MARKERS, BIOLOGICAL;

EID: 33644518241     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000091008     Document Type: Article

References (67)

1. von Wichert G, Jehle PM, Hoeflich A, Koschnick S, Dralle H, Wolf E, Wiedenmann B, Boehm BO, Adler G, Seufferlein T: Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res 2000;60:4573-4581.
2. von Wichert G, Haeussler U, Greten FR, Kliche S, Dralle H, Bohm BO, Adler G, Seufferlein T: Regulation of cyclin D1 expression by autocrine IGF-I in human BON neuroendocrine tumour cells. Oncogene 2005;24:1284-1289.
3. Ahnert-Hilger G, Stadtbaumer A, Strubing C, Scherubl H, Schultz G, Riecken EO, Wiedenmann B: gamma-Aminobutyric acid secretion from pancreatic neuroendocrine cells. Gastroenterology 1996;110:1595-1604.
4. Kowase T, Nakazato Y, Yoko O, Morikawa A, Kojima I: Immunohistochemical localization of growth factor-regulated channel (GRC) in human tissues. Endocr J 2002;49:349-355.
5. Oxford GS, Webb CK: GoLoco motif peptides as probes of Galpha subunit specificity in coupling of G-protein-coupled receptors to ion channels. Methods Enzymol 2004;390:437-450.
6. Maechler P, Wollheim CB: Mitochondrial glutamate acts as a messenger in glucose-induced insulin exocytosis. Nature 1999;402:685-689.
7. Koizumi S, Inoue K: Functional coupling of secretion and capacitative calcium entry in PC12 cells. Biochem Biophys Res Commun 1998;247:293-298.
8. Zeng N, Kang T, Wen Y, Wong H, Walsh J, Sachs G: Galanin inhibition of enterochromaffin-like cell function. Gastroenterology 1998;115:330-339.
9. Zanner R, Hapfelmeier G, Gratzl M, Prinz C: Intracellular signal transduction during gastrin-induced histamine secretion in rat gastric ECL cells. Am J Physiol 2002;282:C374-C382.
10. 2+ channels. Annu Rev Cell Dev Biol 2000;16:521-555.
11. Glassmeier G, Strubing C, Riecken EO, Buhr H, Neuhaus P, Ahnert-Hilger G, Wiedenmann B, Scherubl H: Electrophysiological properties of human carcinoid cells of the gut. Gastroenterology 1997;113:90-100.
12. Glassmeier G, Hopfner M, Riecken EO, Mann B, Buhr H, Neuhaus P, Wiedenmann B, Scherubl H: Inhibition of L-type calcium channels by somatostatins in human neuroendocrine tumor cells of the gut. Ann NY Acad Sci 1998;859:208-209.
13. Glassmeier G, Hopfner M, Riecken EO, Mann B, Buhr H, Neuhaus P, Meyerhof W, Scherubl H: Inhibition of L-type calcium channels by octreotide in isolated human neuroendocrine tumor cells of the gut. Biochem Biophys Res Commun 1998;250:511-515.
14. 2+ channel characteristics in neuroendocrine tumor cell cultures analyzed by color contour plots. J Neurosci Methods 2003;129:169-181.
15. Mergler S, Wiedenmann B, Prada J: R-type Ca(2+)-channel activity is associated with chromogranin A secretion in human neuroendocrine tumor BON cells. J Membr Biol 2003;194:177-186.
16. Mergler S, Drost A, Bechstein WO, Neuhaus P, Wiedenmann B: Ca(2+) channel properties in neuroendocrine tumor cell cultures investigated by whole-cell patch-clamp technique. Ann NY Acad Sci 2004;1014:137-139.
17. Strauss O, Mergler S, Wiederholt M: Regulation of L-type calcium channels by protein tyrosine kinase and protein kinase C in cultured rat and human retinal pigment epithelial cells. FASEB J 1997;11:859-867.
18. Mergler S, Steinhausen K, Wiederholt M, Strauss O: Altered regulation of L-type channels by protein kinase C and protein tyrosine kinases as a pathophysiologic effect in retinal degeneration. FASEB J 1998;12:1125-1134.
19. 2+ channel currents in NG108-15 cells. Pflügers Arch 1998;436:127-132.
20. 2+ channel-insulin-like growth factor-1 receptor signaling impairment in aging rat skeletal muscle. Biochem Biophys Res Commun 1997;235:784-789.
21. Blair LA, Marshall J: IGF-1 modulates N and L calcium channels in a PI 3-kinase-dependent manner. Neuron 1997;19:421-429.
22. Evers BM, Ishizuka J, Townsend CM Jr, Thompson JC: The human carcinoid cell line, BON. A model system for the study of carcinoid tumors. Ann NY Acad Sci 1994;733:393-406.
23. Barry PH: JPCalc, a software package for calculating liquid junction potential corrections in patch-clamp, intracellular, epithelial and bilayer measurements and for correcting junction potential measurements. J Neurosci Methods 1994;51:107-116.
24. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985;260:3440-3450.
25. Piedras-Renteria ES, Chen CC, Best PM: Antisense oligonucleotides against rat brain alpha1E DNA and its atrial homologue decrease T-type calcium current in atrial myocytes. Proc Natl Acad Sci USA 1997;94:14936-14941.
26. Piedras-Renteria ES, Tsien RW: Antisense oligonucleotides against alpha1E reduce R-type calcium currents in cerebellar granule cells. Proc Natl Acad Sci USA 1998;95:7760-7765.
27. Pereverzev A, Vajna R, Putzer G, Hescheler J, Klockner U, Schneider T: Reduction of insulin secretion in the insulinoma cell line INS-1 by overexpression of a Ca(v)2.3 (alpha1E) calcium channel antisense cassette. Eur J Endocrinol 2002;146:881-889.
28. Wiedenmann B, Franke WW, Kuhn C, Moll R, Gould VE: Synaptophysin: a marker protein for neuroendocrine cells and neoplasms. Proc Natl Acad Sci USA 1986;83:3500-3504.
29. Nobels FR, Kwekkeboom DJ, Bouillon R, Lamberts SW: Chromogranin A: its clinical value as marker of neuroendocrine tumours. Eur J Clin Invest 1998;28:431-440.
30. Walts AE, Said JW, Shintaku IP, Lloyd RV: Chromogranin as a marker of neuroendocrine cells in cytologic material: an immunocytochemical study. Am J Clin Pathol 1985;84:273-277.
31. Green WR, Linnoila RI, Triche TJ: Neuroendocrine carcinoma of skin with simultaneous cytokeratin expression. Ultrastruct Pathol 1984;6:141-152.
32. Thordarson G, Slusher N, Leong H, Ochoa D, Rajkumar L, Guzman R, Nandi S, Talamantes F: Insulin-like growth factor (IGF)-I obliterates the pregnancy-associated protection against mammary carcinogenesis in rats: evidence that IGF-I enhances cancer progression through estrogen receptor-alpha activation via the mitogen-activated protein kinase pathway. Breast Cancer Res 2004;6:R423-R436.
33. Wang YZ, Wong YC: Sex hormone-induced prostatic carcinogenesis in the noble rat: the role of insulin-like growth factor-I (IGF-I) and vascular endothelial growth factor (VEGF) in the development of prostate cancer. Prostate 1998;35:165-177.
34. +. Ann NY Acad Sci 2002;971:573-575.
35. Kato H, Faria TN, Stannard B, Roberts CT Jr, LeRoith D: Role of tyrosine kinase activity in signal transduction by the insulin-like growth factor-I (IGF-I) receptor. Characterization of kinase-deficient IGF-I receptors and the action of an IGF-I-mimetic antibody (alpha IR-3). J Biol Chem 1993;268:2655-2661.
36. Chik CL, Li B, Karpinski E, Ho AK: Insulin and insulin-like growth factor-I inhibit the L-type calcium channel current in rat pinealocytes. Endocrinology 1997;138:2033-2042.
37. + channels via PI3-kinase, PDK1 and SGK1. Pflügers Arch 2002;443:625-634.
38. Kanzaki M, Nie L, Shibata H, Kojima I: Activation of a calcium-permeable cation channel CD20 expressed in Balb/c 3T3 cells by insulin-like growth factor-I. J Biol Chem 1997;272:4964-4969.
39. Huang CY, Hao LY, Buetow DE: Insulin-like growth factor-induced hypertrophy of cultured adult rat cardiomyocytes is L-type calcium-channel- dependent. Mol Cell Biochem 2002;231:51-59.
40. Kanzaki M, Zhang YQ, Mashima H, Li L, Shibata H, Kojima I: Translocation of a calcium-permeable cation channel induced by insulin-like growth factor-I. Nat Cell Biol 1999;1:165-170.
41. Matsunaga H, Nishimoto I, Kojima I, Yamashita N, Kurokawa K, Ogata E: Activation of a calcium-permeable cation channel by insulin-like growth factor II in BALB/c 3T3 cells. Am J Physiol 1988;255:C442-C446.
42. Kim JH, Shin SY, Yun SS, Kim TJ, Oh SJ, Kim KM, Chung YS, Hong EK, Uhm DY, Kim SJ: Voltage-dependent ion channel currents in putative neuroendocrine cells dissociated from the ventral prostate of rat. Pflügers Arch 2003;446:88-99.
43. Prinz C, Zanner R, Gratzl M: Physiology of gastric enterochromaffin-like cells. Annu Rev Physiol 2003;65:371-382.
44. Weiergraber M, Pereverzev A, Vajna R, Henry M, Schramm M, Nastainczyk W, Grabsch H, Schneider T: Immunodetection of alpha1E voltage-gated Ca(2+) channel in chromogranin-positive muscle cells of rat heart, and in distal tubules of human kidney. J Histochem Cytochem 2000;48:807-819.
45. Feng ZP, Hamid J, Doering C, Bosey GM, Snutch TP, Zamponi GW: Residue Gly 1326 of the N-type calcium channel alpha 1B subunit controls reversibility of omega-conotoxin GVIA and MVIIA block. J Biol Chem 2001;276:15728-15735.
46. Bourinet E, Soong TW, Sutton K, Slaymaker S, Mathews E, Monteil A, Zamponi GW, Nargeot J, Snutch TP: Splicing of alpha 1A subunit gene generates phenotypic variants of P- and Q-type calcium channels. Nat Neurosci 1999;2:407-415.
47. Mintz IM, Venema VJ, Swiderek KM, Lee TD, Bean BP, Adams ME: P-type calcium channels blocked by the spider toxin omega-Aga-IVA. Nature 1992;355:827-829.
48. Moreno H, Rudy B, Llinas R: beta subunits influence the biophysical and pharmacological differences between P- and Q-type calcium currents expressed in a mammalian cell line. Proc Natl Acad Sci USA 1997;94:14042-14047.
49. Randall AD, Tsien RW: Contrasting biophysical and pharmacological properties of T-type and R- type calcium channels. Neuropharmacology 1997;36:879-893.
50. Stephens GJ, Morris NP, Fyffe RE, Robertson B: The Cav2.1/alpha1A (P/Q-type) voltage-dependent calcium channel mediates inhibitory neurotransmission onto mouse cerebellar Purkinje cells. Eur J Neurosci 2001;13:1902-1912.
51. Lustig HS, Ahern KB, Greenberg DA: Omega-agatoxin IVA and excitotoxicity in cortical neuronal cultures. Neurosci Lett 1996;213:142-144.
52. Fisher TE, Bourque CW: Distinct omega-agatoxin-sensitive calcium currents in somata and axon terminals of rat supraoptic neurones. J Physiol 1995;489:383-388.
53. Bourinet E, Stotz SC, Spaetgens RL, Dayanithi G, Lemos J, Nargeot J, Zamponi GW: Interaction of SNX482 with domains III and IV inhibits activation gating of alpha(1E) (Ca(V)2.3) calcium channels. Biophys J 2001;81:79-88.
54. Newcomb R, Szoke B, Palma A, Wang G, Chen X, Hopkins W, Cong R, Miller J, Urge L, Tarczy-Hornoch K, Loo JA, Dooley DJ, Nadasdi L, Tsien RW, Lemos J, Miljanich G: Selective peptide antagonist of the class E calcium channel from the venom of the tarantula Hysterocrates gigas. Biochemistry 1998;37:15353-15362.
55. Wang G, Dayanithi G, Newcomb R, Lemos JR: An R-type Ca(2+) current in neurohypophysial terminals preferentially regulates oxytocin secretion. J Neurosci 1999;19:9235-9241.
56. McDonald TF, Pelzer S, Trautwein W, Pelzer DJ: Regulation and modulation of calcium channels in cardiac, skeletal, and smooth muscle cells. Physiol Rev 1994;74:365-507.
57. 2+-dependent gonadotropin-releasing hormone release in GT1-7 cells. Endocrinology 2004;145:2375-2383.
58. Scherubl H, Hescheler J, Bychkov R, Cuber JC, John M, Riecken EO, Wiedenmann B: Electrical activity and calcium channels in neuroendocrine cells. Ann NY Acad Sci 1994;733:335-339.
59. 2+ channels and insulin secretion in the insulinoma cell line INS-1. Eur J Biochem 2001;268:1066-1075.
60. 2+ channel in skeletal muscle myoblasts: involvement of a CD20-like protein. J Cell Physiol 2003;197:53-60.
61. 2+ channel and insulin-like growth factor genes in rat atria. Am J Physiol 2005;288:H829-H838.
62. Arnold R, Simon B, Wied M: Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review. Digestion 2000;62 (suppl 1):84-91.
63. Lamberts SW, Reubi JC, Krenning EP: Somatostatin receptor imaging in the diagnosis and treatment of neuroendocrine tumors. J Steroid Biochem Mol Biol 1992;43:185-188.
64. Wynick D, Bloom SR: Clinical review 23: The use of the long-acting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors. J Clin Endocrinol Metab 1991;73:1-3.
65. Martin-Moutot N, de Haro L, Seagar M: Dosage and specificity of anti-calcium channel antibodies in Lambert-Eaton myasthenic syndrome. Rev Neurol (Paris) 2004;160:828-S34.
66. Burns TM, Juel VC, Sanders DB, Phillips LH: Neuroendocrine lung tumors and disorders of the neuromuscular junction. Neurology 1999;52:1490-1491.
67. Demirer T, Ravits J, Aboulafia D: Myasthenic (Eaton-Lambert) syndrome associated with pulmonary large-cell neuroendocrine carcinoma. South Med J 1994;87:1186-1189.